Continuous Dosing Phase I Study of BMS-599626 in Patients With HER2-Expressing Advanced Solid Malignancies
Latest Information Update: 03 Nov 2021
At a glance
- Drugs BMS 599626 (Primary)
- Indications Bladder cancer; Breast cancer; Colon cancer; Gastric cancer; Non-small cell lung cancer; Ovarian cancer
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb